Enveric Biosciences, Inc. (ENVB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.8600 |
| Open | 2.7800 |
| Bid | 2.8600 x 1000 |
| Ask | 2.9100 x 1400 |
| Day's Range | 2.7800 - 2.9550 |
| 52 Week Range | 1.5700 - 34.3500 |
| Volume | |
| Avg. Volume | 46,048 |
| Market Cap | 90.071M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6740 |
| Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 23, 2008 |
| 1y Target Est | 32.50 |
- Business Wire
Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"
CAMBRIDGE, Mass., December 21, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41st Annual J.P. Morgan Health Care Conference in San Francisco
- Business Wire
Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders
CAMBRIDGE, Mass., November 28, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos
- Business Wire
Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference
CAMBRIDGE, Mass., November 16, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, 2022 – December 1, 2022.
